ArticleInternational journal of general medicine2021
Impact of the 2020 China Diabetes Society Guideline on the Prevalence of Diabetes Mellitus and Eligibility for Antidiabetic Treatment in China.
Article in International journal of general medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Effect of the nurse-led program on blood glucose control and microalbuminuria development in type 2 diabetic populations.Medicine · 2022Trial
- Association of anxiety, depressive symptoms, and inflammatory indices with cardiometabolic multimorbidity.Brain, behavior, & immunity - health · 2026Article
- Metabolic syndrome predicts cardiovascular and all-cause adverse outcomes in patients with chronic inflammatory arthritis.Clinical rheumatology · 2026Observational
- A Hospital-Wide informatized glycemic management Team(WH-GMT) improves perioperative outcomes in type 2 diabetes: A prospective cohort study.Endocrine · 2026Article
- Mortality and recurrent events after first hospitalisation for heart failure and pulmonary heart disease: a community-based prospective study of 0.5 million Chinese adults.BMJ public health · 2026Article
- Metformin-based oral antihyperglycemic combination therapy and risk of dementia in patients with newly diagnosed type 2 diabetes: A population-based study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Influence of Internet-Based Health Management on Control of Blood Glucose in Patients with Type 2 Diabetes: A Four-Year Longitudinal Study.Healthcare (Basel, Switzerland) · 2025Article
- Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients With Type 2 Diabetes Mellitus Initiating Basal Insulin Therapy: Prospective Observational Real-World Study.Journal of medical Internet research · 2025Observational
- Metabolic syndrome is associated with prognosis in patients with acute ischemic stroke after intravenous thrombolysis: a prospective cohort study.Frontiers in neurology · 2025Article
- Influence of Type 2 Diabetes Mellitus on the Clinical Outcomes in Hospitalized Patients with Active Pulmonary Tuberculosis: A Retrospective, Single-Center, Real-World Study in China.Infection and drug resistance · 2025Article
- Prospective studies on artificial intelligence (AI)-based diabetic retinopathy screening.Annals of translational medicine · 2022Article
- Self-Monitoring of Blood Glucose as an Integral Part in the Management of People with Type 2 Diabetes Mellitus.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to estimate the impact of the 2020 China Diabetes Society's (CDS) guideline on the prevalence of diabetes mellitus and eligibility for antidiabetic treatment in China. MATERIAL AND
methodsBaseline data from the China Health and Retirement Longitudinal Study (CHARLS, 2011-2012) were used to estimate the prevalence of diabetes mellitus and compare the recommendations for antidiabetic medication and intensification of therapy between the 2017 and 2020 CDS guidelines.
resultsAccording to the 2017 CDS guideline, the prevalence of diabetes mellitus was 12.56% among Chinese adults who were ≥45 years of age. However, according to the 2020 CDS guideline, 0.65% (0.35%, 1.20%), or 3.54 (2.50, 4.57) million Chinese adults who were ≥45 years would additionally be diagnosed with diabetes mellitus. Among Chinese adults not taking antidiabetic medications, 1.06% (0.87%, 1.28%), or 5.37 (4.36, 6.38) million Chinese adults with diabetes mellitus were recommended to start antidiabetic medication according to the 2017 CDS guideline, while 1.27% (1.01%, 1.58%), or 6.44 (5.29, 7.60) million Chinese adults with diabetes would be recommended to initiate antidiabetic medication according to the 2020 CDS guideline. Among Chinese adults taking antidiabetic medication, 51.59% (44.19%, 58.93%), or 18.35 (15.58, 21.12) million Chinese adults with diabetes received antidiabetic treatment but had a hemoglobin A1c (HbA
conclusionThe addition of HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.